home
顺序
主题
题目
日子
56
Doctor William Hearl appointed as the Director of HLB
admin
 
55
Elevar Therapeutics announces enrollment of the first patient in a pivotal trial for the treatment of Adenoid Cystic Cancer (AC
admin
 
54
HLB requests marketing authorization for second-line liver cancer for Rivoceranib
admin
 
53
HLB's acquisiton of Rivoceranib's global rights
admin
 
52
HLB takes over Immunomic Therapeutics
admin
 
51
Elevar Therapeutics acquires Global Rights to European approved Apealea® from Oasmia Pharmaceutical
admin
 
50
JAMA announces Rivoceranib's NSCLC combination therapy
admin
 
49
Immunomic Therapeutics to initiate developing COVID-19 Vaccine
admin
 
48
Rivoceranib approved for phase 3 clinical trial as first-line lung cancer treatment
admin
 
47
Doctor William Hearl appointed as the Director of HLB
admin